Study population
Symptomatic patients with monomorphic RVOT-type VAs and refractory to at
least one antiarrhythmic agent were eligible. Patients were excluded if
they had structural heart disease or successful ablation outside RVOT.
Written informed consents were provided before the procedures. The study
was approved by the ethics committee of Guizhou Provincial People’s
Hospital.